N-(4-Chlorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

Catalog No. :
ACRSJP405
CAS No. :
2096339-42-1
Molecular Formula :
C19H21BClNO3
Molecular Weight :
357.65

IUPAC Name:N-(4-chlorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N-(4-Chlorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$292.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(4-Chlorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
IUPAC NameN-(4-chlorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
Molecular FormulaC19H21BClNO3
Molecular Weight357.65
SMILESO=C(NC1=CC=C(Cl)C=C1)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2
InChI KeyVQRALZPLWWICTD-UHFFFAOYSA-N
SynonymN-(4-Chloro-phenyl)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide;Benzamide, N-(4-chlorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;4'-Chlorobenzanilide-4-boronic acid pinacol ester
CAS No.2096339-42-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACRSJP405 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFXIR245 route compound structure diagram
    ACFXIR245180516-87-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRSJP405 route product structure diagram
    ACRSJP4052096339-42-1
Inquiry

2. ACRSJP405 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRSJP405 route product structure diagram
    ACRSJP4052096339-42-1
Inquiry

Comments (0)